GelStat Sleep

GelStat® Sleep provides relief from sleep disorders and its associated symptoms.  Most adults have experienced insomnia or sleeplessness at one time or another in their lives.  An estimated 30%-50% of the general population is affected by insomnia, and 10% have chronic insomnia. Ambien generated an estimated $1.89 billion in revenues in 2005, accounting for approximately 60% of the total insomnia prescription market, with billions more being spent each year on OTC products such as Nytol, Sleep Eze, and Somnia.   Furthermore, many turn to antihistamines, cold remedies, and tranquilizers to aid in sleep.  This off-label use of these other products makes it very difficult to accurately determine the market size.

Competitive Advantages

• Reduced Time to Fall Asleep
• Increased Quality of Sleep
• No Drowsiness or “Hangover Feeling” the Following Day
• Available OTC without a Prescription
• Numerous Testimonials
• Significant Margins
• Large Market Size
• Potential usage for professionals with irregular sleep patterns (pilots, nurses, machine operators, military personnel.)
• Expected to be Available in the 3rd Quarter of 2014